Latest news with #2024
Qatar Tribune
10 minutes ago
- Politics
- Qatar Tribune
Justice ministry calls for registering POAs issued before 2011
DOHA: The Ministry of Justice has called on citizens and residents with powers of attorney (POAs) issued before 2011 to visit the Ministry's Documentation Department to register these powers of attorney in the designated register. This is in accordance with the provisions of Law No. 1 of 2023 on documentation and Justice Minister's Decision No 156 of 2024 regarding the organization and maintenance of records, registers, and documentation indexes. Director of the Documentation Department at the Ministry, Areej Mohsin Al Shammari, explained that this announcement comes as part of the implementation of the ministerial decision issued in accordance with the aforementioned law. She noted that the registration process requires completing and submitting the designated application form, attaching either the original POA or a certified copy, providing proof of identity for the concerned parties, and, if applicable, submitting any previously issued related POAs. Al Shammari further clarified that applications should be submitted at the Government Services Center - Al Hilal branch, specifically at the data update office. She emphasized that this measure is among the new services introduced by the Ministry pursuant to Article (33) of the Documentation Law, which mandates the creation of an electronic register for all POAs. The law also requires concerned parties to register POAs issued before 2011 within one year from the date the law's provisions come into effect.
Yahoo
41 minutes ago
- Business
- Yahoo
Orphan Drugs Market Size to Hit USD 475.61 Billion by 2032, Driven by Increased R&D Investment and Growing Prevalence of Rare Diseases
SNS Insider Highlights Rapid Expansion of the U.S. Orphan Drugs Market, Valued at USD 56.25 Billion in 2024, Forecasted to Hit USD 123.48 Billion by 2032 Amid Surging Biotech Innovation and Regulatory Incentives. Austin, June 20, 2025 (GLOBE NEWSWIRE) -- Orphan Drugs Market Size & Growth Analysis: According to SNS Insider, the Orphan Drugs Market was valued at USD 190.87 billion in 2024 and is anticipated to reach USD 475.61 billion by 2032, growing at a CAGR of 12.11% during the forecast period (2025–2032). The United States alone accounted for USD 56.25 billion in 2024 and is projected to hit USD 123.48 billion by 2032. The primary growth catalysts include rising public and private investment in R&D, gene-based therapies, favorable reimbursement policies, and expanding patient a Sample Report of Orphan Drugs Market@ Market Overview Orphan drugs for treating diseases that afflict less than 200,000 individuals in the U.S. are attracting more than ever before from regulators and pharmaceutical innovators. The FDA's Orphan Drug Act and complementary legislation from the EMA have spurred market action by providing advantages such as market exclusivity, fee reductions, tax credits, and expedited approval channels. These instruments greatly alleviate commercial risks involved in developing drugs for small patient bases. Pharma giants and biotech companies are pouring into the space, drawn by large margins and longer terms of exclusivity. Concurrently, technologies like gene therapy, CRISPR, monoclonal antibodies, and cell-based treatments are allowing precision medicines with revolutionary results. The U.S. is still at the forefront of orphan drug development, fueled by robust R&D spending, swift FDA approval times, and growing collaborations between academia, biopharma, and patient organizations. Government initiatives and expanded access avenues are making treatments more broadly available to those suffering from rare disease. Major Players Analysis Listed in this Report are: Amgen Inc. Bayer AG F. Hoffmann-La Roche Ltd Alexion Pharmaceuticals Inc. Novo Nordisk A/S Novartis AG Bristol-Myers Squibb Company AstraZeneca Daiichi Sankyo Company Limited GlaxoSmithKline Orphan Drugs Market Report Scope Report Attributes Details Market Size in 2024 USD 190.87 billion Market Size by 2032 USD 475.61 billion CAGR (2025–2032) 12.11% U.S. Market 2024 USD 56.25 billion U.S. Forecast by 2032 USD 123.48 billion Base Year 2024 Forecast Period 2025–2032 Key Regional Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis By Therapy Type The orphan drugs market was dominated by the oncology segment with a share of 38.7 % in 2024. This hegemony is due to the high level of unmet need and increasing prevalence of orphan cancers like glioblastoma and neuroendocrine tumors. Because of the fast-track approval paths - especially for cancer drugs - it's tempting for drugmakers to target these types of treatments. By Drug Type Biologics led the market in 2024 with 72%, on account of better target specificity and high efficiency for the treatment of rare diseases. Monoclonal antibodies, gene therapies, and recombinant proteins have made a breakthrough in the development of orphan drugs by delivering disease-modifying results in contrast to the palliative effects. By Distribution Channel Hospital pharmacy services held the major share of the distribution side with a share of 58% globally in 2024. It is mainly because orphan drugs are generally liable to special management, administration by hospital workers, and patient follow-up, which are easier to perform in a hospital. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Orphan Drugs Market Segmentation By Therapy Type Oncology Hematology Neurology Endocrinology Cardiovascular Respiratory Immunotherapy Infectious Diseases Others By Drug Type Biologics Non-biologics By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Others Regional Analysis North America led the orphan drugs market in 2024, driven by favorable government legislation like the Orphan Drug Act, faster approval processes, high healthcare expenditure, and the dominant presence of key biopharma companies. The U.S. holds the largest share due to its strong regulatory support, early diagnosis capabilities, and strategic collaborations in rare disease drug development. Asia Pacific is the fastest-growing region, propelled by rising awareness, increasing diagnosis rates, and growing government focus on rare diseases in countries like Japan, China, and South Korea. The expanding biopharma infrastructure and investment in local orphan drug R&D also contribute to rapid regional growth. Recent Developments (Orphan Drugs Market) March 2025 – FDA granted orphan drug designation to radiprodil (GRIN Therapeutics) for GRIN-related neurodevelopmental disorder; Phase 3 trial planned for 2025. August 2024 – NXP800 by Nuvectis Pharma received orphan drug designation for ARID1a-deficient ovarian and peritoneal cancers. April 2024 – Pfizer launched Elrexfio for relapsed/refractory multiple myeloma under orphan status in the U.S. Buy a Single-User PDF of Orphan Drugs Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Orphan Drugs Market by Therapy Type 8. Orphan Drugs Market by Drug Type 9. Orphan Drugs Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@ in to access your portfolio
Barnama
an hour ago
- Barnama
Perak Syariah Judiciary Launches eKSPerk Portal To Simplify Case Registration
IPOH, June 20 (Bernama) -- The Perak Syariah Judiciary Department has developed the Modul Awam Elektronik Kehakiman Syariah Perak (eKSPerk) website to facilitate the preparation of registration forms for selected syariah court cases. Perak Chief Syariah Judge Datuk Ab Rahman Thobroni Mohd Mansor said the website, accessible at has been operational since June 10. He said cases eligible for registration through eKSPerk include consensual divorce applications, confirmation of divorce pronouncements, underage marriage applications and the appointments of wali hakim. 'This public module was developed to assist individuals without legal representation who often face difficulties in preparing court documents. 'Previously, the public found it challenging to engage document writers due to high fees charged by some. With eKSPerk, users can fill in the necessary case details and information more conveniently,' he told reporters after the 2024 Perak Syariah Judiciary Department Excellence Appreciation Ceremony here today. Ab Rahman Thobroni said that, for now, users must print out the completed forms and submit them to the court manually. 'We are working to upgrade the website so that, in the future, documents filled in via eKSPerk can be directly integrated into the e-syariah system,' he said. He said registration forms prepared by third parties or individuals are still accepted, as long as they comply with the required format, content structure and language style. 'At present, the Perak Syariah Judiciary Department is the only one implementing such a module, but it may be adopted by syariah judiciary departments in other states,' he said.
Globe and Mail
an hour ago
- Business
- Globe and Mail
Is Rocket Lab USA Stock a Buy Now?
Over the past few decades, private companies have expanded the possibilities of space exploration and research. According to estimates from consultancy McKinsey, the space economy is projected to grow to $1.8 trillion by 2035. With such substantial growth ahead and innovation across the industry, the space economy is emerging as a potentially significant investment opportunity. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » While companies like SpaceX lead the way, they remain private. Alternatives like Rocket Lab USA (NASDAQ: RKLB) are making waves in the small-satellite launch market, and it is the second-most utilized launch provider in the U.S. The space company is expanding its services, including lunar exploration and satellite deployment, in response to increasing demand. Here's what investors should know about Rocket Lab and its long-term opportunity today. Second in space launches in the U.S. Rocket Lab USA, founded in 2017, has enjoyed strong demand for its services over the past several years. The company generated $436.2 million in revenue in 2024, representing a 78% increase from the previous year. Strong growth has been driven by increasing demand, as evidenced by its rising backlog of orders, which now stands at $1.1 billion. That sizable figure indicates strong demand and provides some visibility into its future revenue generation. The company anticipates recognizing about 56% of this backlog as revenue over the next year. Since its founding, Rocket Lab has completed 66 launch missions, including 16 in 2024, making it the No. 2 launch company in the U.S. However, it remains well behind SpaceX, which launched 132 rockets last year and has larger rockets and the ability to transport bigger payloads. Rocket Lab aims to close this gap with its Neutron rocket, which it expects to launch sometime this year. The rocket represents a significant development for Rocket Lab since it will allow transport of larger payloads -- nearly 40 times larger than its Electron launch vehicle. This capability is vital as demand for launching satellites and other cargo continues to grow. The larger rocket will also enable Rocket Lab to compete for larger contracts and achieve higher profits and margins per launch. Pursuing every part of the space value chain Besides its launch vehicles, Rocket Lab is carving out a niche in the space systems section of the broader space economy. For example, it acquired the German company Mynaric for $75 million. It provides laser optical- communications terminals for air, space, and mobile applications. By acquiring Mynaric, Rocket Lab can scale up production of optical communication terminals, which are crucial for satellite-to-satellite connectivity. The German company was already a subcontractor for Rocket Lab, and the integration will give it greater control over its supply chain, allowing it to operate more efficiently. CEO Peter Beck said that his company would pursue every part of the space value chain and that it was "closing in on the final step and most valuable part of the space economy: operating our own constellations to provide data and services from space." Rocket Lab's finances As an investor evaluating opportunities within the aerospace sector, it's crucial to analyze the current financial state of Rocket Lab. Delays in the launch of the Neutron rocket could hinder its near-term prospects and would likely weigh on the stock in the short term. Furthermore, the company is grappling with sizable operational losses, reflecting its high cash burn, which may be a red flag for conservative investors seeking stability. Last year, revenue was $436.2 million while the cost of revenue and operating expenses soared to $626 million. As a result, the company had an operating loss of $190 million. This trend continued in the first quarter, with an operating loss of $59 million on $122.5 million in revenue. RKLB Revenue (Quarterly) data by YCharts. Rocket Lab has expressed optimism about its path toward profitability. Analysts project the company could achieve positive cash flow by 2026 and earnings by 2027. Is Rocket Lab USA right for you? Rocket Lab's future is bright. Its backlog of orders is significant, and it has been included as part of the U.S. Space Force's $5.6 billion National Security Space Launch program. As part of this, Rocket Lab has been selected to compete for the Department of Defense's national security missions for its National Security Space Launch (NSSL) Phase 3 Lane 1 program. If chosen, its success here could lead to stable and potentially lucrative contracts over the long term. As investors, we must strike a balance between risk and reward and understand what we are getting into. Rocket Lab USA is a fast-growing company in the emerging space economy. It is positioning itself not just as a launch company, but as one that also operates across the entire space value chain. Rocket Lab's current financials may deter those seeking steady, reliable returns. However, for growth-focused investors, today could be an opportunity to get in at ground level with a company in an industry expected to experience significant growth in the years to come. Should you invest $1,000 in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
The Drive
2 hours ago
- Automotive
- The Drive
Maserati Might Be For Sale Soon: Report
The latest car news, reviews, and features. A new CEO walks in the door at Stellantis on Monday and things might be up in the air for the automaker's sole luxury brand. On Friday, Reuters reported Stellantis might put Maserati up for sale to cut its losses as the automotive giant overhauls its operations. The McKinsey consultant group was hired by Stellantis in April to reportedly take stock of how U.S. tariffs will affect Maserati and Alfa Romeo. Stellantis had planned for both of these brands, neither of which produces vehicles in the U.S., to go electric in the coming years with entire revamps of their product lines. Reuters reported two sources said among the options McKinsey is in the early stages of exploring for Stellantis is the 'possible divestment of Maserati.' A Stellantis spokesperson told Reuters , 'Respectfully, Maserati is not for sale.' The Drive reached out to Maserati for comment but hadn't heard back as of the time of publishing. Maserati has been flailing despite the introduction of new high-end product including the MC20 sports car, GT2 Stradale, and GranCabrio. The GranCabrio, in Folgore trim, marked the first and currently only electric convertible on the market today. In February, during the parent company's 2024 earnings call CFO Doug Ostermann said the company wrote down a $1.59 billion investment in Maserati. Part of that was 'the cancellation of projects prior to launch,' according to the company's investor deck. Maserati sales dropped 58% in 2024 with 11,300 vehicles sold compared to 26,600 the prior year. The drop in sales translated to an adjusted operating loss of 260 million euros ($299 million). With an electric future in sight Maserati killed its V-8 engine in 2023. But earlier in 2025 Maserati killed its electric supercar, which was to be called the MC20 Folgore, noting a lack of customer demand. It's believed that electric supercar was either done or nearly done and ready to launch soon. Stellantis CEO Carlos Tavares resigned in December. The automaker's board chair, John Elkann, has been steering the ship while the automaker interviewed CEO candidates. Antonio Filosa, a current Stellantis executive who's served as the CEO of Jeep among other positions, will step in as the new Stellantis CEO on Monday. Got tips? Send 'em our way at tips@
